妊娠合并Ph阳性急性淋巴细胞白血病危重患者的无化疗诱导治疗:一例报告及文献复习
报道一例36岁孕28周确诊Ph阳性急性淋巴细胞白血病的危重患者,病情迅速恶化为弥散性血管内凝血、弥漫性肺泡出血、脓毒症休克及多器官功能障碍。采用伊马替尼联合地塞米松的无化疗诱导方案并强化支持治疗,患者达到完全缓解,后续完成巩固化疗、CAR-T细胞治疗及异基因造血干细胞移植,长期随访持续完全分子学缓解。
要点
- 妊娠合并Ph阳性急性淋巴细胞白血病危重患者可采用伊马替尼联合地塞米松的无化疗诱导方案。
- 强化支持治疗包括机械通气、连续性肾脏替代治疗、广谱抗感染及大剂量糖皮质激素至关重要。
- 该方案安全有效,可为类似危重妊娠患者提供治疗思路。
核心结论
- 对于妊娠合并Ph阳性急性淋巴细胞白血病的危重患者,在强化支持治疗基础上采用靶向药物联合糖皮质激素的无化疗方案安全有效。
研究设计与样本
- 个案报告及文献复习,报道一例36岁孕28周确诊Ph阳性急性淋巴细胞白血病的危重患者。
主要发现
- 患者病情迅速恶化,出现弥散性血管内凝血、弥漫性肺泡出血、脓毒症休克及多器官功能障碍,转入血液科重症监护病房。
- 采用伊马替尼联合地塞米松的无化疗诱导方案,同时予气管插管机械通气、连续性肾脏替代治疗、广谱抗感染及大剂量糖皮质激素等综合支持治疗。
- 治疗期间胎儿胎死宫内,经产科干预娩出死胎。
- 经积极救治,患者呼吸衰竭、弥散性血管内凝血及弥漫性肺泡出血逐步改善,白血病达完全缓解。
- 后续完成巩固化疗、嵌合抗原受体T细胞治疗及异基因造血干细胞移植,长期随访显示持续完全分子学缓解。
临床怎么用
- 对于妊娠合并Ph阳性急性淋巴细胞白血病的危重患者,可考虑在强化支持治疗基础上采用伊马替尼联合地塞米松的无化疗诱导方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This report presents the management of a critically ill 36-year-old woman diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL) at 28 weeks of gestation. The patient rapidly deteriorated, developing disseminated intravascular coagulation (DIC) , diffuse alveolar hemorrhage (DAH) , septic shock, and multi-organ dysfunction, necessitating admission to the hematological intensive care unit. Given her critical condition and advanced pregnancy, a chemotherapy-free induction regimen comprising imatinib and dexamethasone was initiated, alongside comprehensive supportive measures, including mechanical ventilation, continuous renal replacement therapy (CRRT) , broad-spectrum antibiotics, and high-dose corticosteroids. During treatment, intrauterine fetal demise occurred, and a stillborn was delivered following obstetric intervention. With aggressive treatment, the patient's respiratory failure, DIC, and DAH gradually resolved, and she achieved complete remission. She subsequently received consolidation chemotherapy, CAR-T cell therapy, and allogeneic hematopoietic stem cell transplantation, achieving sustained complete molecular remission on long-term follow-up. This case demonstrates that for critically ill pregnant patients with Ph(+) ALL, a chemotherapy-free regimen of targeted therapy and corticosteroids, when combined with intensive supportive care, is a safe and effective approach that may offer a therapeutic option for similar cases. 报道1例妊娠合并Ph阳性急性淋巴细胞白血病(Ph(+)ALL)危重患者的救治经验。患者为36岁女性,孕28周时确诊Ph(+) ALL,病情迅速恶化,出现弥散性血管内凝血(DIC)、弥漫性肺泡出血(DAH)、脓毒症休克及多器官功能障碍,转入血液科重症监护病房。鉴于患者病情危重且处于妊娠晚期,采用伊马替尼联合地塞米松的"无化疗"诱导方案,同时予气管插管机械通气、连续性肾脏替代治疗(CRRT)、广谱抗感染及大剂量糖皮质激素等综合支持治疗。治疗期间胎儿胎死宫内,经产科干预娩出死胎。经积极救治,患者呼吸衰竭、DIC及DAH逐步改善,白血病达完全缓解,后续完成巩固化疗、嵌合抗原受体T细胞治疗及异基因造血干细胞移植,长期随访显示持续完全分子学缓解。表明对于妊娠合并Ph(+)ALL的危重患者,在强化支持治疗基础上,采用靶向药物联合糖皮质激素的"无化疗"方案安全有效,可为类似患者提供治疗思路。.
引用
- Gao M, Xie Y, Liu ZY, et al. [Chemotherapy-free induction therapy for a critically ill pregnant woman with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41339052. doi:10.3760/cma.j.cn121090-20250519-00235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。